Literature DB >> 8708569

Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats.

H Stepień1, M Grochal, K W Zieliński, S Mucha, J Kunert-Radek, A Kulig, A Stawowy, H Pisarek.   

Abstract

The process of angiogenesis occurs in many physiological states, but it is also essential for the growth of solid tumours and metastasis formation. An abnormal arterial vascularization has been shown in prolactin-secreting pituitary adenomas induced by prolonged treatment with oestrogens in Fischer 344 (F344) rats. It is thought that anti-angiogenic agents might be useful in therapy for these tumours. Fumagillin and its analogue TNP-470 are known to inhibit endothelial cell proliferation selectively, but their effect on lactotroph cell secretory function and prolactinoma formation has not yet been described. The aim of the present study was to examine the effects of fumagillin and TNP-470 on prolactin secretion, and morphological and vascular changes within the anterior pituitary in long-term oestrogen-treated male F344 rats in vivo and in vitro. As expected, 7 weeks after s.c. implantation of Silastic tubes containing 10 mg diethyl-stilboestrol (DES), a very high rise in serum prolactin levels was found. Both angiogenesis inhibitors injected s.c. at doses of 10 mg/kg body weight for 24 days attenuated the stimulatory effect of DES on prolactin production and release. They also diminished prolactin cell density and inhibited cell proliferation expressed as the number of anterior pituitary cells labelled with bromodeoxyuridine (BrdU), but the effect of TNP-470 was minor compared with fumagillin. Both angioinhibitors suppressed neo-vascularization within the anterior pituitary with similar potency but, on the other hand, they did not affect DES-induced increases in prolactin secretion from cultured rat pituitary cells and cell proliferation in vitro. In conclusion, our results provide strong evidence for the anti-tumour and anti-prolactin activity of angiogenesis inhibitors in the experimentally oestrogen-induced pituitary adenoma; this might be mediated indirectly through the inhibition of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8708569     DOI: 10.1677/joe.0.1500099

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  10 in total

1.  Global analysis of gene expression in the estrogen induced pituitary tumor of the F344 rat.

Authors:  Douglas L Wendell; Adrian Platts; Susan Land
Journal:  J Steroid Biochem Mol Biol       Date:  2006-09-26       Impact factor: 4.292

2.  Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas.

Authors:  Anna Gruszka; Jolanta Kunert-Radek; Marek Pawlikowski; Henryk Stepien
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 3.  Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour.

Authors:  N Garcia de la Torre; H E Turner; J A H Wass
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 4.  Estrogen action in the regulation of cell proliferation, cell survival, and tumorigenesis in the rat anterior pituitary gland.

Authors:  T J Spady; R D McComb; J D Shull
Journal:  Endocrine       Date:  1999-12       Impact factor: 3.633

5.  Expression of leukemia inhibitory factor in human pituitary adenomas: a morphologic and immunocytochemical study.

Authors:  G Kontogeorgos; H Patralexis; A Tran; K Kovacs; S Melmed
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

6.  Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat.

Authors:  Slawomir A Mucha; Gabriela Meleń-Mucha; Andrzej Godlewski; Henryk Stepień
Journal:  Virchows Arch       Date:  2007-01-18       Impact factor: 4.064

7.  Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.

Authors:  María Susana Mallea-Gil; Carolina Cristina; María Inés Perez-Millan; Ana M Rodriguez Villafañe; Carolina Ballarino; Graciela Stalldecker; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

8.  Tissue-specific actions of the Ept1, Ept2, Ept6, and Ept9 genetic determinants of responsiveness to estrogens in the female rat.

Authors:  Scott G Kurz; Kimberly K Hansen; Mac T McLaughlin; Vijay Shivaswamy; Beverly S Schaffer; Karen A Gould; Rodney D McComb; Jane L Meza; James D Shull
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

9.  Immunocytochemical Investigations on the Vascularization of Pituitary Adenomas.

Authors:  Marek Pawlikowski; Hanna Pisarek; Maria Jaranowska
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

10.  Angiogenesis in Endocrine Neoplasms.

Authors:  Martin Jugenburg; Kalman Kovacs; Ivan Jugenburg; Bernd W. Scheithauer
Journal:  Endocr Pathol       Date:  1997       Impact factor: 4.056

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.